Abstract:BackgroundsAlzheimer’s disease (AD) is a multifactorial neurodegenerative disease. The treatment of AD through multiple pathological targets may generate therapeutic efficacy better. The multifunctional molecules that simultaneously hit several pathological targets have been of great interest in the intervention of AD.MethodsHere, we combined the chalcone scaffold with carbamate moiety and 5,6-dimethoxy-indanone moiety to generate a novel multi-target-directed ligand (MTDL) molecule (E)-3-((5,6-dimethoxy-1-oxo-1,3-dihydro-2H-inden-2-ylidene)-methyl)phenylethyl(methyl) carbamate (named AP5). In silico approaches were used to virtually predict the binding interaction of AP5 with AChE, the drug-likeness, and BBB penetrance, and later validated by evaluation of pharmacokinetics (PK) in vivo by LC-MS/MS. Moreover, studies were conducted to examine the potential of AP5 for inhibiting AChE and AChE-induced amyloid-β (Aβ) aggregation, attenuating neuroinflammation, and providing neuroprotection in the APP/PS1 model of AD.ResultsWe found that AP5 can simultaneously bind to the peripheral and catalytic sites of AChE by molecular docking. AP5 exhibited desirable pharmacokinetic (PK) characteristics including oral bioavailability (67.2%), >10% brain penetrance, and favorable drug-likeness. AP5 inhibited AChE activity and AChE-induced Aβ aggregation in vivo and in vitro. Further, AP5 lowered Aβ plaque deposition and insoluble Aβ levels in APP/PS1 mice. Moreover, AP5 exerted anti-inflammatory responses by switching microglia to a disease-associated microglia (DAM) phenotype and preventing A1 astrocytes formation. The phagocytic activity of microglial cells to Aβ was recovered upon AP5 treatment. Importantly, chronic AP5 treatment significantly prevented neuronal and synaptic damage and memory deficits in AD mice.ConclusionTogether, our work demonstrated that AP5 inhibited the AChE activity, decreased Aβ plaque deposition by interfering Aβ aggregation and promoting microglial Aβ phagocytosis, and suppressed inflammation, thereby rescuing neuronal and synaptic damage and relieving cognitive decline. Thus, AP5 can be a new promising candidate for the treatment of AD.

Silibinin Inhibits Acetylcholinesterase Activity and Amyloid Β Peptide Aggregation: a Dual-Target Drug for the Treatment of Alzheimer's Disease.

Silymarin’s Inhibition and Treatment Effects for Alzheimer’s Disease

Inhibition of Aβ Amyloid Growth and Toxicity by Silybins: The Crucial Role of Stereochemistry

Silibinin Ameliorates Formaldehyde-Induced Cognitive Impairment by Inhibiting Oxidative Stress

Regulation of Gut Microbiota in Alzheimer’s Disease Mice by Silibinin and Silymarin and Their Pharmacological Implications

Alleviation of Symptoms of Alzheimer's Disease by Diminishing Aβ Neurotoxicity and Neuroinflammation.

Silibinin ameliorates STING-mediated neuroinflammation via downregulation of ferroptotic damage in a sporadic Alzheimer's disease model

Formulation and Characterization of Silibinin Entrapped Nano-Liquid Crystals for Activity against Aβ1-42 Neurotoxicity in In-Vivo Model

A Novel Multifunctional 5,6-Dimethoxy-indanone-chalcone-carbamate Hybrids Alleviates Cognitive Decline in Alzheimer’s Disease by Dual Inhibition of Acetylcholinesterase and Inflammation

Evaluation of Natural Flavonoid Compounds in Amyloid-β (Aβ) Inhibition for Alzheimer’s Disease Treatment

Lipoprotein-Inspired Nanoscavenger for the Three-Pronged Modulation of Microglia-Derived Neuroinflammation in Alzheimer’s Disease Therapy

Design, synthesis, and evaluation of dual‐target inhibitors for the treatment of Alzheimer's disease

Development of silibinin-loaded nanostructured lipid carriers for Alzheimer's disease induced by amyloid beta in Wistar rats

Silibinin Inhibits the Toxic Aggregation of Human Islet Amyloid Polypeptide

The Combined Treatment of Amyloid-Β1-42-stimulated Bone Marrow–derived Dendritic Cells Plus Splenocytes from Young Mice Prevents the Development of Alzheimer's Disease in APPswe/PSENldE9 Mice

Inhibition of Lysozyme Amyloid Fibrillation by Silybin Diastereoisomers: The Effects of Stereochemistry

Silicon-Carbon Dots-Loaded Mesoporous Silica Nanocomposites (msio2@sicds): an Efficient Dual Inhibitor of Cu2+-Mediated Oxidative Stress and A Aggregation for Alzheimer's Disease

Inhibition of Amyloid Β Aggregation and Cytotoxicity by Berbamine Hydrochloride.

Silicon-Carbon Dots-Loaded Mesoporous Silica Nanocomposites (mSiO2@SiCDs): An Efficient Dual Inhibitor of Cu2+-Mediated Oxidative Stress and Aβ Aggregation for Alzheimer's Disease.

SIL1 improves cognitive impairment in APP23/PS45 mice by regulating amyloid precursor protein processing and Aβ generation

Self-Assembly Molecular Chaperone to Concurrently Inhibit the Production and Aggregation of Amyloid Β Peptide Associated with Alzheimer’s Disease